Ottimo Pharma
Ottimo Pharma is a private biotechnology company, co-founded in 2020 by Medicxi and Jonny Finlay, focused on the development of pioneering innovative cancer therapies for solid tumors. The Company's lead program, Jankistomig, is a PD1-VEGFR2 bi-functional antibody designed to target both immune checkpoint inhibition and angiogenesis in a single IgG therapy. By advancing this dual-pathway approach, Ottimo Pharma aims to improve cancer treatment outcomes and reduce overall healthcare burden. The Company boasts a world-class leadership team, including David Epstein as Chair and CEO, Mehdi Shahidi as Head of Development and CMO, and James Sabry as Vice-Chair of the Board. Ottimo Pharma anticipates filing an IND in late 2025.
7-day free trial · no credit card
Verified contacts
17
available on Kipplo
LinkedIn employees
20
1 to 10 range
Open roles
—
no listings
Distinct roles
2
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 17 verified contacts at Ottimo Pharma
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
17 contacts with verified email or phone · masked until revealed.
- WE
Whitney Escalante
Associate Director, Clinical Operations · Science
EmailPhone - SS
Susan Singer
Director of Executive Administration and Operations · Other
EmailPhone
Showing 2 of 17 verified contacts
Top roles at Ottimo Pharma
2 distinct titles indexed · top 2 shown.
- 1associate director, clinical operations
- 1director of executive administration and operations
Sign up to unlock all 17 contacts at Ottimo Pharma
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 17 verified contacts at Ottimo Pharma
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.